Sequenom shares fall on Down syndrome test patent row; Breast size genetic markers predict breast cancer risk;

> Sequenom shares fall as a U.S. District Court decides against blocking a competitor's Down syndrome marker blood test. Article

> Epigenetic osteoarthritis markers could point to new drugs. Press release | Abstract

> Japanese researchers have suggested that C-reactive protein (CRP) could be used as a prognostic marker in patients with advanced renal cell carcinoma (RCC) treated with sunitinib. Article

> Oxford University researchers have identified 20 novel fibrosis biomarker candidates that may help to assess hepatic fibrosis and eliminate the need for invasive liver biopsies. Abstract | Blog post

> Diagnostics company Saladax Biomedical has extended the availability of its MyCare blood tests to optimize dosing of cancer drugs. Press release

> University of Buffalo researchers are hunting for urine biomarkers for autism. Press release

> Cardiac biomarker troponin T predicts death up to a month after surgery. Press release | Abstract

> Genisphere and the Lankenau Institute for Medical Research have extended their microRNA (miRNA) biomarker development collaboration to include Crohn's disease and other inflammatory bowel disorders. Press release

> TNF levels could link treatment response and inflammation in bipolar disorder. Article

> HPV infection markers have a new role in head and neck cancer. Press release | Abstract

> A fragment of titin, a muscle-specific protein, could be a biomarker for heart damage. Abstract

And Finally… Breast size genetic markers predict breast cancer risk, according to 23andMe. Press release | Abstract

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.